HIV-1-induced neuronal injury in the developing brain

被引:68
作者
Epstein, LG
Gelbard, HA
机构
[1] Univ Rochester, Dept Neurol, Rochester, NY 14627 USA
[2] Univ Rochester, Dept Pediat, Rochester, NY 14627 USA
[3] Univ Rochester, Dept Microbiol, Rochester, NY 14627 USA
[4] Univ Rochester, Dept Immunol, Rochester, NY 14627 USA
[5] Univ Rochester, Dept Pharmacol, Rochester, NY 14627 USA
关键词
central nervous system; apoptosis; pathogenesis; blood-brain barrier; neuroprotection;
D O I
10.1002/jlb.65.4.453
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
HIV-1 infection of the nervous system causes neuronal injury and death, resulting in cognitive, motor, and behavioral dysfunction in both adults and children. in infants a characteristic feature of HIV-1 infection is impaired brain growth resulting in secondary microcephaly with onset between 2 and 4 months of age. This post-natal period of brain development is particularly vulnerable to excitotoxic neuronal injury due to the active synaptogenesis and pruning that takes place at this age associated with over-expression of excitatory amino acid (EAA) receptors, HIV-1 infection of brain microglia and perivascular macrophages results in chronic inflammation manifest pathologically as diffuse microglial activation and reactive astrogliosis. Several inflammatory products of activated microglia, including tumor necrosis factor alpha (TNF-alpha) and platelet-activating factor (PAF) have been shown to act as neuronal toxins. This toxic effect can be antagonized by blocking NMDA (or AMPA) glutamate receptors, suggesting that (weak) excitotoxicity leads to oxidative stress, neuronal injury, and apoptosis. HIV-1 infection and chronic inflammation may also contribute disruption of the blood-brain barrier and could result in further entry into the CNS of toxic viral or cellular products or additional HIV-l-infected cells, We hypothesize that prolonged microglial activation during HIV-1 infection underlies the neuronal injury and impaired brain growth in affected infants. Further investigation of the interaction between HIV-1-infected/activated microglia and developing neurons seems warranted. The current understanding of HIV neuropathogenesis implies that therapeutic strategies should target the sustained immune activation hi microglia, attempt to repair the integrity of the blood-brain barrier, and provide '"neuroprotection" from excitotoxic neuronal injury.
引用
收藏
页码:453 / 457
页数:5
相关论文
共 63 条
[41]   Rett syndrome: A disorder affecting early brain growth [J].
Naidu, S .
ANNALS OF NEUROLOGY, 1997, 42 (01) :3-10
[42]  
NAMURA Y, 1994, ACTA NEUROCHIR, P296
[43]   Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures [J].
New, DR ;
Ma, MH ;
Epstein, LG ;
Nath, A ;
Gelbard, HA .
JOURNAL OF NEUROVIROLOGY, 1997, 3 (02) :168-173
[44]   HIV-1 Tat induces neuronal death via tumor necrosis factor-α and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism [J].
New, DR ;
Maggirwar, SB ;
Epstein, LG ;
Dewhurst, S ;
Gelbard, HA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17852-17858
[45]  
NOTTET HSLM, 1995, J IMMUNOL, V154, P3567
[46]   Platelet-activating factor receptor activation - An initiator step in HIV-1 neuropathogenesis [J].
Perry, SW ;
Hamilton, JA ;
Tjoelker, LW ;
Dbaibo, G ;
Dzenko, KA ;
Epstein, LG ;
Hannun, Y ;
Whittaker, JS ;
Dewhurst, S ;
Gelbard, HA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17660-17664
[47]  
Persidsky Y, 1996, AM J PATHOL, V149, P1027
[48]  
PETITO CK, 1995, AM J PATHOL, V146, P1121
[49]   ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONATE AND KAINATE DIFFERENTLY AFFECT NEURONAL CYTOARCHITECTURE OF RAT CEREBELLAR GRANULE CELLS [J].
PIZZI, M ;
FALLACARA, C ;
CONSOLANDI, O ;
MEMO, M ;
SPANO, PF .
NEUROSCIENCE LETTERS, 1994, 166 (01) :77-80
[50]   CEREBRAL WHITE-MATTER CHANGES IN ACQUIRED-IMMUNODEFICIENCY-SYNDROME DEMENTIA - ALTERATIONS OF THE BLOOD-BRAIN-BARRIER [J].
POWER, C ;
KONG, PA ;
CRAWFORD, TO ;
WESSELINGH, S ;
GLASS, JD ;
MCARTHUR, JC ;
TRAPP, BD .
ANNALS OF NEUROLOGY, 1993, 34 (03) :339-350